Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Organ Transplantation Clear all
Completed Phase 2Phase 3 Interventional Results available

Naloxone for Optimizing Hypoxemia Of Lung Donors

NCT02581111
View directory record Official record
Conditions
Brain Death, Organ Donors, Lung Transplantation
Interventions
Naloxone, Normal saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
13 Years to 70 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Denver, Colorado • Metairie, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 21, 2026, 9:22 PM EDT
Completed No phase listed Observational

Donors After Cardiac Death: Validating Identification Criteria

NCT00177606
View directory record Official record
Conditions
Withdrawing Treatment
Interventions
withdrawal of life sustaining treatments
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Jul 21, 2026, 9:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914
View directory record Official record
Conditions
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
Interventions
Tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT05121142
View directory record Official record
Conditions
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 21, 2026, 9:22 PM EDT
Active, not recruiting No phase listed Observational

OCS™ Lung TOP Registry For Donor Lungs for Transplantation

NCT03639025
View directory record Official record
Conditions
Lung Transplantation
Interventions
OCS Lung System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

NCT01329185
View directory record Official record
Conditions
EBV Viremia, CMV Viremia
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 21, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT05550298
View directory record Official record
Conditions
Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

Donors After Circulatory Death Heart Trial

NCT03831048
View directory record Official record
Conditions
Heart Transplant
Interventions
OCS Heart System, Cold Storage
Device · Other
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
25
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 21, 2026, 9:22 PM EDT
Recruiting No phase listed Observational

Biomarkers in Transplant Recipients to Improve Outcomes

NCT01163578
View directory record Official record
Conditions
Solid Organ Transplantation, Bone Marrow Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 9:22 PM EDT
Not yet recruiting Phase 4 Interventional

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

NCT07426484
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancer
Interventions
Cosibelimab, Prednisone, Sirolimus, Everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 21, 2026, 9:22 PM EDT
Recruiting Early Phase 1 Interventional

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

NCT07286318
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions
Topical niacinamide 5% cream, Sunscreen
Drug
Lead sponsor
Marissa Lobl
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

University Student Intervention to Increase Organ Donation

NCT01969864
View directory record Official record
Conditions
Organ Donation, Health Behavior
Interventions
HRSA Video Intervention, PI Video Intervention, CDC Health Website Intervention
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
2,261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
3
States / cities
Berea, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function

NCT02162511
View directory record Official record
Conditions
Malignant Diseases, Non-malignant Diseases
Interventions
CliniMACS CD34+ cell enrichment and T-cell depletion
Device
Lead sponsor
Rajni Agarwal
Other
Eligibility
Up to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jul 21, 2026, 9:22 PM EDT
Terminated Not applicable Interventional

Goal of Open Lung Ventilation in Donors

NCT03439995
View directory record Official record
Conditions
Brain Death, Organ Donation, Organ Transplant Failure or Rejection
Interventions
Open lung protective ventilation, Conventional ventilation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Jul 21, 2026, 9:22 PM EDT
Terminated Phase 3 Interventional

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

NCT03995901
View directory record Official record
Conditions
Transplanted Organ Rejection
Interventions
FCR001
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

NCT02866695
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ingenol mebutate gel 0.015%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 21, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

NCT04807777
View directory record Official record
Conditions
Advanced Cutaneous Squamous Cell Carcinoma
Interventions
Ruxolitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations

NCT06027229
View directory record Official record
Conditions
Immunosuppression, COVID-19
Interventions
NVX-CoV2372
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

Remote Ischemic Preconditioning in Neurological Death Organ Donors

NCT01515072
View directory record Official record
Conditions
Organ Transplantation
Interventions
RIPC (Remote Ischemic Preconditioning)
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
6 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Newark, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Jul 21, 2026, 9:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Registry for Organ Transplantation From COVID Positive Donors.

NCT05595837
View directory record Official record
Conditions
COVID-19, Organ Transplant
Interventions
Standard organ transplant
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation

NCT05038943
View directory record Official record
Conditions
Heart Transplant Failure, Determination of Death, Outcomes Research, Extracorporeal Membrane Oxygenation
Interventions
Paragonix SherpaPak Cardiac Transport System
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

NCT00307125
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
Interventions
Rituximab plus immunosuppression, Placebo plus immunosuppression
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 70 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 21, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Monitoring Organ Donors to Increase Transplantation Results (MOnIToR)

NCT00987714
View directory record Official record
Conditions
Transplantation
Interventions
Protocolized care
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
16 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
8
States / cities
Norcross, Georgia • Cleveland, Ohio • Columbus, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 21, 2026, 9:22 PM EDT
Recruiting Phase 4 Interventional

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

NCT06958796
View directory record Official record
Conditions
Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications, Simultaneous Liver-Kidney Transplantation; Complications
Interventions
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
Drug
Lead sponsor
Camille N. Kotton, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 21, 2026, 9:22 PM EDT